Search PubMed⌕ Search

Biomedical subjects

I Fukui

Publications and source records attributed to I Fukui.

At least 127 records · Page 7Linked to original sources
PubMed1984

[Combination chemotherapy with bleomycin, vinca alkaloid and cisplatin (BVP) for advanced urothelial cancer].

Since October 1979, 18 patients with metastatic urothelial cancer have been treated with combination chemotherapy of bleomycin (5-10 mg/day administered on days 1 to 7), vinca alkaloid (vinblastine 5-10 mg/day or vincristine 1 mg/sqm on days 8 and 9) and CDDP (60 mg/sqm on day 10). CR was achieved in 3 of the 18 patients and PR in 6 patients. Over-all, the response rate was 50%. Among 3 patients who achieved CR, 2 patients are still free of disease for 31 months and for 28 months, and the other is alive with cancer for 26 months. The 2-year survival rate was 58% in responders (CR + PR) and 0% in nonresponders. (p less than 0.005). In many cases, the response was observed after the first or second course of BVP therapy, and there was a relatively good response in patients with lymphnode metastasis alone. The treatment was tolerated well and common toxic effects were nausea, vomiting of moderate to severe degree (100%), myelosuppression (50%) and mild nephrotoxicity (22%). As to the choice of vinca alkaloids, vincristine seemed to be the treatment of choice because it was less toxic than vinblastine and was almost equally effective.

Aged↗
PubMed1984

[Adjuvant chemotherapy following total cystectomy for invasive bladder cancer with bleomycin, vincristine and methotrexate].

Eleven patients with invasive bladder cancer were treated with combination chemotherapy consisting of bleomycin (5 mg, i.m., day 1-7), vincristine (1 mg/sq.m.i.v., day 8) and methotrexate (200-300 mg/sq.m.i.v. day 8). Chemotherapy was started about 4 weeks following total cystectomy and repeated every 2 or 3 weeks at least for one year. Five of the patients were free of disease at the mean follow-up time of 35.6 months, ranging from 21 to 50 month. The 3-year survival rate was 54.5%. Bone marrow suppression (36%), nausea and vomiting (55%) were observed, but they were not serious and well tolerated. These results suggest that this regimen could be used safely as an adjuvant chemotherapy following total cystectomy for patients with invasive bladder cancer. Further evaluation will be necessary.

Adult↗
PubMed1984

[Bleomycin, vinca alkaloid and cis-diamminedichloroplatinum combination chemotherapy for advanced testicular tumors].

Thirteen patients with advanced testicular tumors (seminoma 2, non-seminoma 11) were treated with combination chemotherapy involving BLM, vinca alkaloid and CDDP (BVP) as induction therapy and followed with CPM, VCR and CDDP as maintenance therapy. BVP and COP administration was repeated every 3 and 4 to 8 weeks for 1 year, if there were no serious side effects. The overall response rate (CR + PR) was 92% with a 69% CR rate. At a mean follow-up of 30 months (7-52 month range), 54% of the patients were alive with no evidence of disease. Bulky metastases, failure to respond to prior chemotherapy and teratomatous metastases were considered to be poor prognostic factors. The toxicity of BVP was similar to that reported for CDDP, except that allergic reaction occurred in 3 patients after several courses of treatment. Two of the 3 went into anaphylactic shock.

Adult↗
PubMed1984

[HCG-positive cells in seminoma of the testis].

In a retrospective study of 38 patients with pure seminoma, serum and urine levels of human chorionic gonadotropin (HCG) were measured and the cellular origin of HCG-like substance was searched using the technique of indirect immunoperoxidase on step sections of the tumors. Eight of the patients had elevated HCG in serum or urine, and 5 had HCG-positive cells in the sections of tumor specimens. With this technique, two types of HCG-positive cells were identified, syncytiotrophoblastic giant cells (STGC) and mononuclear cells otherwise indistinguishable from seminoma cells. Patients in the present series responded well to conventional radiation therapy or cytotoxic chemotherapy and had a favorable outcome regardless of the presence of STGC or slightly elevated HCG levels.

Adult↗
PubMed1984

[Allergic reaction to CDDP: report of 4 cases].

Four cases of CDDP allergic reaction (CDDP reaction) are reported. CDDP was given intravenously with vinka-alkaloid and bleomycin or cyclophosphamide (CDDP combination therapy). Case 1 was a 59-year-old man with left ureteral squamous cell carcinoma. The tumor was so large and infiltrated into the retroperitoneal space, that he had conservatively undergone only left nephrectomy and tumor biopsy. Post-operative CDDP combination therapy was performed. Soon after the beginning of the 6th CDDP drip-infusion, a reaction to CDDP occurred. Case 2 was a 22-year-old man diagnosed to have left testicular embryonal carcinoma with multiple pulmonary metastases. After radical orchiectomy and retroperitoneal lymphadenectomy, CDDP combination therapy was performed. At the beginning of the 8th CDDP drip-infusion, a reaction to CDDP occurred. Case 3 was a 49-year-old man diagnosed to have non-papillary bladder carcinoma. Although his bladder was tumor free by TUR-Bt, distant lymph node metastases occurred. CDDP combination therapy was performed. At the beginning of the 6th CDDP drip-infusion, a reaction to CDDP occurred. Case 4 was a 64 year-old-man diagnosed to have bladder carcinoma which was recurrent from right renal pelvic tumor. After total cystectomy and ileal conduit, CDDP combination therapy was performed for diffuse retroperitoneal lymph nodes metastases. At the beginning of the 8th CDDP drip-infusion, a reaction to CDDP occurred. Reaction to CDDP developed at the 6th to 8th course of combination chemotherapy with CDDP, i.e., 450 to 700 mg of CDDP in total doses.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1984

[Phase II study of UFT for malignant tumors of urinary organs].

Phase II Study of UFT was performed in 59 patients with malignant tumors of urinary organs in 5 Cooperative Study Institutions. Forty-nine patients out of 59 were evaluable for response according to Koyama -Saito's criteria. Complete response (CR) was recorded in 7 patients, partial response (PR) in 3, minor response in 2, no change in 27 and progressive disease in 10, respectively. The overall response rate was 20.4%. The response classified in terms of tumor type was as follows: 4 CR and 2 PR of 23 patients with bladder tumor, response rate of 26.1%; 1 CR and 2 PR of 10 patients with renal tumor, response rate of 30.0%; 1 CR of 12 patients with prostatic tumor, response rate of 8.3%. Side effects occurred in 22 (41.5%) out of 53 patients. The high incidence was mainly concerned with GI toxicity such as anorexia (24.5%), nausea and vomiting (9.4%), general malaise (9.4%), diarrhea (3.8%) and stomatitis (3.8%), respectively. Renal function disorder was not induced, and marrow depression and hepatic function disorder occurred at low frequency (1 case each).

Adult↗
PubMed1984

[The effects of DDP on the seminiferous epithelium of rats].

Adult male rats were injected intraperitoneally with 2 mg, 4 mg and 6 mg Cis-diamminedichloroplatinum (DDP) per kg body weight. The animals were then sacrificed on the 7th, 24th or 35th day. Two specimens of testis from each rat were stained by H.E. technique, then the Pachytene primary spermatocytes and Sertoli cells in the cross sectioned tubules at stage IV-V, IX-X and XIII-XIV were counted. Significant decrease of Pachytene/Sertoli(P/S) valueinstage IX-X tubules on the 24th day (p less than 0.01) suggests that DDP has a cytotoxic effect on early differentiated type A spermatogonia (A1).

Animals↗
PubMed1983

In vivo staining test with methylene blue for bladder cancer.

An in vivo staining test with 0.2 per cent methylene blue was applied to 129 patients with bladder tumor and 16 patients with chronic cystitis within a 6-year interval. Although normal mucosa did not pick up the stain nonpapillary in situ and microinvasive carcinomas did so frequently. Moderate dysplasia was stained in about half of the patients. The intensity of the stain in papillary tumors was correlated with the histologic anaplasia (grade). Grade 1 tumors were stained poorly or unstained in 86 per cent of the tests, whereas grades 2 and 3 tumors picked up the stain in 74 and 96 per cent of the tests, respectively. Even a tiny tumor, if poorly differentiated, was identified easily by the blue stain. The histologic anaplasia of tumors could be assessed roughly according to the intensity of the stain. However, chronic cystitis occasionally took up the stain, especially in cases of marked inflammatory infiltrate a deep stain was recognized. To differentiate nonpapillary early cancer from chronic cystitis the addition of a cytologic examination may be necessary.

Biopsy↗
PubMed1983

Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.

Gliclazide has been reported to decrease platelet function and to inhibit the progression of diabetic retinopathy in addition to having a hypoglycemic effect. To confirm these effects we performed a double-blind randomized study using glibenclamide as a reference drug. Thirty-eight hospitals from eight university groups in Japan performed the study on type II diabetic subjects. Evaluation of blood glucose control, platelet adhesiveness, platelet aggregation and blood lipids over 24 weeks were assessed by the central committee. Two hundred and eighty-nine patients were enrolled in the study. Twelve were excluded and 277 were statistically analysed. Homogeneity between the two diabetic groups was demonstrated for background factors. Forty mg of gliclazide was comparable to 2.5 mg of glibenclamide in the potency of hypoglycemic efficacy. Funduscopic aggravations were observed in a statistically smaller number of cases in the gliclazide group than in the glibenclamide group and in evaluation of serum lipids, the gliclazide group was also superior to the glibenclamide group. No significant difference between the two groups was found in platelet adhesiveness and aggregation. Gliclazide is a useful drug in the therapy of diabetes mellitus.

Adult↗
PubMed1983

[Combination chemotherapy with bleomycin, vincristine and methotrexate for stage I non-seminomatous germ cell testicular tumors].

Ten patients with Stage I non-seminomatous germ cell testicular tumors underwent orchiectomy and combination chemotherapy with bleomycin, vincristine and methotrexate with CF rescue (BOM) as an induction therapy followed by cyclophosphamide, vincristine and methotrexate as a maintenance therapy (COM). The results were as follows: BOM seemed to be effective as a further treatment for Stage I non-seminomatous germ cell testicular tumor patients. All 10 patients are alive and disease-free for a period from 1 year and 6 months to 5 years and 3 months (mean: 3 years and 9 months). The chemotherapy should be continued at least for a year, since relapse occurred in 2 of 4 patients who received only induction therapy. However, they completely responded to other chemotherapy regimens (BVP and BOAM ). BOM and COM therapy were scarcely toxic and no serious side effects were recognized. From the above results, it was considered that combination chemotherapy (BOM and COM) can be an alternative treatment to the conventional retroperitoneal node dissection and radiation therapy for Stage I non-seminomatous germ cell tumors.

Adult↗
PubMed1983

[Problems in urinary bladder cancer in the aged].

In general, the result of treatment for bladder cancer in elderly patients over 70 years seems less favorable than younger patients. The analysis of case records of our clinic suggests two responsible factors. First, proportion of invasive to superficial cancer is higher in elderly than younger patient; the proportions are 37, 35, 29, 23 and 18%, in ninth, eighth, seventh, sixth and under-sixth decade respectively. Second, the cause of death indifferent to primary cancer is more frequent in elderly than younger patient. Main intercurrent diseases are hepatic, cerebro-vascular, cardio-pulmonary diseases, and cancer of other organs. It is concluded that, superficial cancer should be distinguished more accurately from invasive cancer and treated more properly especially in elderly patient.

Aged↗
PubMed1983

[Mucosal hyperplasia of the ileum after subtotal colectomy in rats].

To evaluate factors contributing to ileal mucosal hyperplasia following extensive colectomy, the following three models were designed in rats: Subtotal colectomy and end-to-end ileoproctostomy; retransection of the terminal ileum with end-to-side proximal-ileoproctostomy (colectomy group), End-to-side ileoproctostomy without colectomy (bypass group), and End-to-side ileocecostomy (control group). In all groups the terminal ileum was left out of the intestinal stream as defunctionalized segments. Specimens were obtained from the terminal ileum during operation and from both the functioning and the defunctionalized segments at various intervals postoperatively. The mucosal hyperplasia was evaluated by measuring eight variables including numbers of villi around the bowel circumference, villous height, crypt depth, total mucosal thickness, epithelial cell counts per villus, DNA contents per unit length of the bowel and radioactivity of incorporated 3H-thymidine as well as DNA specific activity. The results showed that marked mucosal hyperplasia of the functioning segments was noted in all groups, and that mucosal hyperplasia was also observed in defunctionalized segments of colectomized rats, but not in those of both bypass rats and control. These findings were statistically confirmed by analysis of variance. It was concluded that although intraluminal factors played an important role in mucosal hyperplasia of the ileum following extensive colectomy, humoral factors might be also involved in intestinal adaptation.

Animals↗